Media.Player

Gene sequences associated with virally induced cancers

Technology Benefits

-- Targeting LANA2 specifically will cut down on the side effects associated with chemotherapy or other treatments that target rapidly dividing cells.-- Targeting LANA2 specifically will also eliminate the need to use costly and unstable antiviral therapies. This will also help eliminate the resistance that viruses gain from prolonged exposure to antiviral agents. -- LANA2-specific therapies could prove to be more effective than any current therapeutic regime as it targets the specific infection rather than the general process. -- Monoclonal antibodies against LANA2 could more accurately detect KSHV/HHV8 infected cells than histology or other means of detection.-- Virally derived B-cell specific promoter sequences could direct gene expression in gene therapy approaches without the concern of mammalian-promoter specific gene silencing.Patent information: 6,653,465 ~ see link below.

Technology Application

-- The interaction of LANA2 with p53 is a novel target for the development of therapeutics for the treatment of KSHV/HHV8-related cancers in Castleman's disease or primary effusion lymphoma.-- Knowledge of the specific viral LANA2 gene sequence will allow development of RNAi and RNA antisense-based therapeutics.-- Monoclonal antibodies could be used to identify the origin of tumors in the clinic or as a lab reagent.-- B-cell specific promoter region can be used to direct gene expression to hematopoietic tissues in gene therapy.-- Use of LANA2 sequence in transfection could immortalize primary cell cultures.

Detailed Technology Description

Kaposi's sarcoma-associated herpesvirus gene (KSHV/HHV8) LANA2 is a novel therapeutic target in virally induced cancers in Castleman's disease and primary effusion lymphoma.Kaposi's sarcoma-associated herpesvirus (KHSV) or human herpesvir...

*Abstract

None

*Inquiry

Peter GolikovColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR

1089

*Principal Investigator

*Publications

C. Rivas, A. Thick, C. Parravicini, P. Moore, Y. Chang. Kaposi's Sarcoma-Associated Herpesvirus LANA2 Is a B-Cell-Specific Latent Viral Protein that Inhibits p53. Journal of Virology, Vol. 75, Issue 1, Jan. 2001, pp. 429-438.

*Web Links

Issued Patent: 6,653,465

Country/Region

USA